JV to expand Chi-Med's China sales capabilities
This article was originally published in Scrip
Executive Summary
Hutchison China MediTech (Chi-Med) is to spend $9.8m in cash to acquire a majority stake in a Chinese pharma sales operation currently owned by the Sinopharm Group.